Family · Pharmaceutical analytical standards
Levosimendan
A calcium sensitiser developed in Finland and first approved in Sweden in 2000 for acute heart failure: by binding troponin C it makes the heart more sensitive to calcium and strengthens contraction, while it widens blood vessels by opening potassium channels. This family brings together the active ingredient, nitrosamines and other impurities.
Did you know?The drug itself is cleared in about an hour, but one of its active metabolites has a half-life of about 80 hours: this is why the effects of a 24-hour infusion can last for several days.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
